<DOC>
	<DOCNO>NCT02766270</DOCNO>
	<brief_summary>The management lower-grade glioma ( Diffuse low-grade intermediate-grade glioma , WHO II III ) largely base surgery follow radiotherapy . Recent study show lower-grade glioma patient IDH wild-type ( IDH-wt ) TERT promoter mutation ( TERTp-mut ) dismal clinical outcome . These result suggest current treatment strategy adequate subtype lower-grade glioma . The present study aim examine efficacy safety concurrent chemoradiotherapy temozolomide follow adjuvant temozolomide lower- grade glioma patient IDH-wt TERTp-mut .</brief_summary>
	<brief_title>CCRT With Temozolomide Versus RT Alone Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas</brief_title>
	<detailed_description>Diffuse low-grade intermediate-grade glioma ( together make lower-grade glioma , World Health Organization grade II III ) infiltrative neoplasms arise often cerebral hemisphere adult include astrocytomas , oligodendrogliomas , oligoastrocytomas . The management lower-grade glioma largely base surgery follow radiotherapy . Lower-grade glioma highly variable clinical behavior adequately predict basis histologic class . Consequently , clinician increasingly rely genetic classification guide clinical decision making . Mutations IDH1 IDH2 characterize majority lower-grade glioma adult define subtype associate favorable prognosis . Mutations telomerase reverse transcriptase ( TERT ) promoter , result enhance telomerase activity lengthen telomere , observe several human cancer include glioma . Accumulating evidence suggest TERT promoter mutation another molecular marker stratify lower-grade glioma prognostic subgroup combination IDH mutation . In previous study , patient ( 28/377 , 7.4 % ) lower-grade glioma IDH wild-type ( IDH-wt ) TERT promoter mutation ( TERTp-mut ) poor clinical outcome ( median OS , 27.7mo ; 5-year OS , 29 % ) . These result accordant recent study suggest current treatment strategy adequate subtype lower-grade glioma . Radiotherapy plus temozolomide emerge new standard care patient good PS non-elderly glioblastoma . There data support temozolomide adjuvant therapy lower-grade glioma . Given IDH-wt/TERTp-mut subgroup lower-grade glioma dismal prognosis , aggressive therapy concurrent chemoradiotherapy seem reasonable . The present study aim examine efficacy safety concurrent chemoradiotherapy temozolomide follow adjuvant temozolomide lower-grade glioma patient IDH-wt TERTp-mut . Half patient randomly assign receive concurrent chemoradiotherapy ( surgery + concurrent chemoradiotherapy temozolomide follow adjuvant temozolomide ) half patient randomly assign receive conventional therapy ( surgery + radiotherapy ) .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically confirm supratentorial Diffuse lowgrade intermediategrade glioma ( World Health Organization grade II III ) IDH wildtype TERT promoter mutation Age &gt; 18 Karnofsky performance score &gt; 60 Neutrophilic granulocyte count &gt; 1500/µl Platelet count &gt; 100 000/µl Hemoglobin &gt; 10 g/dl Serum creatinine &lt; 1.5 time lab 's upper normal limit AST ALT &lt; 1.5 time lab 's upper normal limit Adequate medical health participate study No previous systemic chemotherapy No previous radiotherapy brain Written inform consent Serious medical neurological condition poor prognosis Contraindications radiotherapy temozolomide chemotherapy Patient unable follow procedure , visit , examination describe study Second cancer require radiotherapy chemotherapy Inability undergo gadoliniumcontrasted MRIs Pregnant woman nurse mother participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Grade II/III Glioma</keyword>
	<keyword>IDH</keyword>
	<keyword>TERT</keyword>
	<keyword>Chemoradiotherapy</keyword>
	<keyword>Temozolomide</keyword>
</DOC>